



Fortnightly TAG Mail – resources list

13 March 2025

NSW TAG ACTIVITIES

Open email discussions

Use of inpatient medicinal cannabis vapes

Scenario: A patient who is using prescribed, legally obtained non-registered medicinal cannabis vape (dry leaf and smoking) was admitted as an inpatient and wanted to use their own medicinal cannabis, which was brought into hospital. There is currently no specific guidance relating to the use of medicinal cannabis vapes - however, there is general smoking policies (which states that all NSW Health facilities are smoke free). This is in a context where use of medicinal cannabis, especially vapes has rapidly increased in recent years and more patients are presenting who are on pre-existing medicinal cannabis vapes.

How is your LHD/N/hospital managing these types of situations? **Closes 2/4/2025**

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AIM: Evaluation and Management of CKD: 2024 Clinical Practice Guideline - [link](#)
AJHP: The role of artificial intelligence in emergency medicine pharmacy practice - [link](#)
ArthRheum: Effectiveness of JAKis Compared With BDMARDS on Pain Reduction in RA- [link](#)
BJCP: Safety and effectiveness of lecanemab for early Alzheimer's disease- [link](#) ;TGA - [link](#)
BJCP: GPT-4's accuracy answering clinical pharmacological questions on pain therapy - [link](#)
BJCP: Factors influencing physicians' antimicrobial prescribing decisions- [link](#)
BJCP: Methotrexate toxicity and glucarpidase: A call for dose optimization - [link](#)
BMJ: Primary prevention of heart attacks and strokes: the polypill approach - [link](#)
BMJ Open: Efficacy & safety of 11 SGLT2i in type 2 DM inadequately controlled with metformin- [link](#)
BMJ Open: Allopurinol use and risk of acute coronary syndrome in gout patients- [link](#)
CCM: A Focused Update to the CPGs for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU - [link](#)
CDA: Cost-Effectiveness and Budget Impact of Nirmatrelvir/Ritonavir, Remdesivir, and Tocilizumab for COVID-19- [link](#)
CMAJ: Effect of emergency department opioid prescribing on health outcomes - [link](#)
Cochrane: Antidepressants for low back pain and spine-related leg pain - [link](#)
EHJ: Great debate: default duration of dual antiplatelet treatment after PCI in ACS- [link](#)
EJHP: Unit dose drug dispensing systems in hospitals - [link](#)
Heart: Evolution of coronary stents: innovations, antithrombotic strategies and future directions - [link](#)
IJQHC: Look-Alike, Sound-Alike Medication Perioperative Incidents in a Regional Australian Hospital: Assessment using a Novel Medication Safety Culture Assessment Tool - [link](#)
IMJ: Results of rapid plasma DOAC levels greatly expand stroke thrombolysis eligibility: - [link](#)
IMJ: Retrospective cohort study of general medicine heart failure management - [link](#)
JAC: The TARGET antibiotic checklist in England's community pharmacies - [link](#)
JAMA: Cardiovascular Outcomes with Icosapent Ethyl by Baseline LDL-C - [link](#)
JAMA Card: Viewpoint: Simultaneous or Rapid Initiation of Combination Therapy for HFpEF - [link](#)
JAMA Derm: Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis - [link](#)
JPPP: Medication-focused telehealth interventions to reduce the hospital readmission rate - [link](#)
JPS: Ambulatory medication errors and adverse events involved in medicine-related malpractice - [link](#)
Lancet GH: The urgent need for implementation science to achieve hepatitis C elimination - [link](#)
Lancet Onc: Dose optimisation to improve access to effective cancer medicines - [link](#)
MJA: A future for the hospital-in-the-home (HITH) deteriorating patient: shifting the paradigm - [link](#)
MJA: Potentially preventable medication-related hospitalisations with CVD of ATSI people- [link](#)
NEJM: Supporting the Development of Drugs for Rare Diseases -Regulatory Transparency - [link](#)
NIHR Commentaries: Which drugs are best for migraine attacks? - [link](#)
Nuffield Trust Quality Watch: Antibiotic prescribing - [link](#)

Pharmacotherapy: Hyponatremia among older adults exposed to SSRIs and thiazide diuretics - [link](#)
Pharmacotherapy: Potentially inappropriate medications among older adults receiving PD- [link](#)
Thorax: Impact of COPD on CV risk factors and outcomes in people with established CVD- [link](#)
SPS: Advising on missed or delayed doses of medicines - [link](#)
TGA: Risk of neurodevelopmental disorders in children born to men taking sodium valproate - [link](#)
WHO: Use of lower-sodium salt substitutes- [link](#)

OTHER NEWS

NSW Health

- Tropical Cyclone Alfred – Information for pharmacists - [link](#)
- Smoke-Free Health Care ([PD2025_009](#)) [07 March 2025]
- Notifiable Conditions Data Security and Confidentiality ([PD2025_008](#)) [28 February 2025]

TGA

- TGA confirms decision to not register lecanemab (LEQEMBI) - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

- Specialised chronic pain management in children and young people - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Documenting oxygen therapy and response for safety - [link](#) – [fact sheet](#)

Australian Government Department of Health

- Biosimilar medicine fact sheet – [enoxaparin](#) - [bevacizumab](#) – [adalimumab](#)
- Handbook of tools to support medicine management in multimorbidity and polypharmacy - [link](#)
- Medication Management Review Programs dataset - [link](#)
- AVALglucosidase alfa Terms of Reference and Protocol Questions - [link](#)

CATAG

MAIA Optimising implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) toolkit.

The toolkit can assist Medicines and Therapeutic Committees support local stewardship of HFrEF management. The toolkit consists of:

- **Practice Tool** – Provides an overview of the GDMT-recommended quadruple therapy for managing HFrEF and presents possible strategies to optimise GDMT implementation.
- **Teaching tool**– Provides a clinical example that educators can use to demonstrate medication optimisation for HFrEF.

Please share and disseminate these resources with your Medicines and Therapeutics Committees, Directors of Pharmacy, your colleagues and anyone within your network who may be interested in these resources. For your convenience, we have attached a flyer that can be shared within your networks.

MIMS monthly updates

- New Products
 - Fenfluramine (hydrochloride) ([Fintepla](#)) - add-on therapy in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older
 - Indocyanine green ([Verdye](#)) - diagnostic agent for the measurement of cardiac output, stroke volume, circulating blood volumes, cerebral perfusion; liver blood flow, excretory function of the liver; and perfusion of the choroid
- New Presentation
 - Clobetasol propionate (Xobet) now as [cream](#) and [ointment](#) for short-term treatment of resistant or severe inflammatory and pruritic manifestations of steroid responsive dermatoses, including psoriasis (excluding widespread plaque psoriasis), recalcitrant dermatoses, lichen sclerosus/planus and discoid lupus erythematosus in adults

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- New Indications
- Blinatumomab ([Blinicyto](#)) now also indicated for the treatment of B-cell precursor acute lymphoblastic leukaemia in the consolidation phase in combination with chemotherapy in patients with Philadelphia chromosome negative disease, and in combination with a tyrosine kinase inhibitor in patients with Philadelphia chromosome positive disease who are unable to receive chemotherapy
- Durvalumab ([Imfinzi](#)) in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy after surgery, now indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements
- Letermovir ([Prevymsis](#)) now also indicated for the prophylaxis of CMV disease in adult kidney transplant recipients at high risk (donor CMV-seropositive/recipient CMV-seronegative)

PBS

- PBS item supply for formerly private prescription items (e.g. Yaz®, Yasmin® listed - [1 March 2025](#))
- Shortages of hormone replace therapy (HRT) patches: PBS subsidy and substitution of Estradot, Estraderm MX and overseas alternatives - [4 March 2025](#)
- Update to Continued Dispensing Arrangements – Emergency Measures - [5 March 2025](#)
- PBAC Public Summary Documents – November 2024 meeting - [7 March 2025](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
- [Eladynos](#) approved for osteoporosis in postmenopausal women at increased risk of fracture

REPORTS AND PUBLICATIONS – INTERNATIONAL

Agency for Healthcare Research and Quality (AHRQ) USA

- Association of Digestible Carbohydrate Intake With Cardiovascular Disease, Type 2 Diabetes, Obesity, and Body Composition - [link](#)

All Wales Medicines Strategy Group

- Managing medicines shortages in Wales - [link](#) - [new webpage](#)

Canadian Agency for Drugs and Technologies in Health

- Crushed Buprenorphine-Naloxone Tablets - [link](#)
- Drug Shortages in Canada — [Expert Panel](#)
- Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis – [final protocol](#)
- Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment of COVID-19 - [link](#)
- Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19 - [link](#)
- Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19 - [link](#)
- Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment of COVID-19 - [link](#)

Department of Health and Social Care UK

- The regulation of artificial intelligence as a medical device: government response to the RHC - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
- Akizza (ethinylestradiol/gestodene) 75mcg/20mcg tablets – for oral contraception and recognised gynaecological indications for such oestrogen-progestogen combinations. The decision to prescribe should consider the individual woman's current risk factors, particularly those for VTE.
- Andembry (garadacimab) 200mg pre-filled pen - human monoclonal antibody targeting IgG4 for routine prevention of recurrent attacks of hereditary angioedema in adults and adolescent patients aged over 12 years. Administered monthly subcutaneously
- Filsapri (sparsentan) tablets– RAS-acting agent for adults with primary immunoglobulin A nephropathy with urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ≥ 0.75 g/g)
- [Revised SPCs](#)

- Esperoct (turoctocog alfa pegol) - use extended to all age groups for treatment & prophylaxis of bleeding due to haemophilia A. Paediatric dosing advice & info from paediatric studies included.
- Evkeeza (evinacumab) - use in paediatric patients aged 6 months and above included, as an adjunct to diet and other LDL-C lowering therapies, for homozygous familial hypercholesterolaemia
- OPDIVO (nivolumab) - use in combination with chemotherapy as neoadjuvant treatment, continued as monotherapy as adjuvant treatment after surgical resection, for treatment of adults with resectable NSCLC & no known EGFR mutations or ALK rearrangements

Epilepsy Society UK

- MPs call for urgent review into medicines shortages - [letter](#)

European Medicines Agency (EMA)

- New clinical trial map launched in the EU - [link](#)
- European CHMP recommends:
 - a change to the existing indication for daratumumab ([Darzalex](#))
 - acalabrutinib ([Calquence](#)) for the treatment of mantle cell lymphoma
 - [Abrysvo](#) (RSV vaccine) in younger adults
 - [beremagene](#) geperpavec for dystrophic epidermolysis bullosa
 - [Deqsig](#) (human normal immunoglobulin)
 - iptacopan ([Fabhalta](#)) for the treatment of adults with complement 3 glomerulopathy
 - [Kaftrio](#) (ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) for use in patients with at least one non-class I CFTR mutation
 - [linvoseltamab](#) (Lynozytic) for multiple myeloma
 - [Trabectedin Accord](#) for the treatment of soft tissue sarcoma and ovarian cancer
 - trastuzumab deruxtecan ([Enhertu](#)) for adults with unresectable or metastatic HR-positive HER2-low or -ultralow breast cancer
 - [glofitamab](#) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
 - Chikungunya vaccine ([Ixchig](#)) for use in younger children
 - durvalumab ([Imfinzi](#)) for the treatment of adults with resectable NSCLC at high risk of recurrence
 - guselkumab ([Tremfya](#)) for treatment of ulcerative colitis
 - letermovir ([Prevmis](#)) for use in children
 - pirtobrutinib ([Jaypirca](#)) for the treatment of adults with relapsed or refractory chronic lymphocytic
 - [Supemtek Tetra](#) (Quadrivalent influenza vaccine) for use in younger children
 - upadacitinib ([Rinvoq](#)) for the treatment of giant cell arteritis
 - ustekinumab ([Stelara](#)) for use in children with Crohn's disease
- European CHMP refuses marketing authorisation for temozolomide ([Kizfio](#))

Food and Drug Administration (FDA) USA

- New Drug approvals
 - Gomekli ([mirdametinib](#)) to treat neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
 - Romvimza ([vimseltinib](#)) to treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
 - Omlyclo ([omalizumab-igec](#)) SC injection for certain allergic/inflammatory/autoimmune conditions
 - Encelto ([revakinagene taroretcel-lwey](#)), an allogeneic encapsulated cell-based gene therapy for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel)
 - TNKase ([tenecteplase](#)) to treat acute ischemic stroke (AIS) in adults
 - Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis)

Health Innovation Network, UK

- The mechanics of tackling overprescribing and problematic polypharmacy - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- approves mRESVIA respiratory syncytial virus (RSV) vaccine to protect patients ≥ 60 years - [link](#)

- MHRA collaboration with hospital DNA sequencing service cuts time to diagnose infections - [link](#)
- approves Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) to treat cystic fibrosis (CF) - [link](#)
- approves lazertinib (Lazcluze) in combination with amivantamab for 1st-line treatment of advanced NSCL cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations - [link](#)

Monthly Index of Medical Specialities MIMS UK

- MIMS learning: Management of diabetes during Ramadan - [link](#)
- Melatonin prescribing options compared in new MIMS table - [link](#)
- Women's health product updates: HRT shortage, fezolinetant liver alert and new generics - [link](#)

NHS England

- Etanercept and adalimumab for deficiency of adenosine deaminase type 2 (≥ 5 years) - [link](#)
- Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over) - [link](#)
- Clinical response to local incidents and outbreaks of infectious disease: Commissioning guidance for Integrated Care Boards - [link](#)
- Neighbourhood health guidelines 2025/26 – [link](#)

NHS Scotland

- Accepted for use:
 - [Cabozantinib](#) (Cabozantinib Ipsen) for the treatment of hepatocellular carcinoma
 - [Talazoparib](#) (Talzenna®) for the treatment of metastatic castration-resistant prostate cancer
- Not recommended:
 - [Ripretinib](#) (Qinlock®) for the treatment of advanced gastrointestinal stromal tumour (GIST)
 - [Spesolimab](#) (Spevigo®) for the treatment of generalised pustular psoriasis

National Institute for Health and Care Excellence (NICE) UK

- 12 SQ-HDM SLIT for allergic rhinitis and allergic asthma caused by house dust mites ([TA1045](#))
- Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma ([TA1046](#))

National Institute for Health and Care Research (NIHR)

- NIHR Commentaries: COVID-19 vaccine during pregnancy reduces risks to mother and baby - [link](#)
- NIHR Commentaries: Which drugs are best for migraine attacks? - [link](#)
- NIHR Evidence: Adult social care- how to improve support for people at risk through homelessness, learning disabilities or dementia - [link](#)
- NIHR commentaries: Vaping is linked with breathing issues in young people - [link](#)
- The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks - [link](#)

Nuffield Trust

- QualityWatch: Antibiotic prescribing - [link](#)

Scottish Intercollegiate Guideline Network (SIGN) UK

- Prevention and remission of type 2 diabetes ([SIGN 172](#))

Specialist Pharmacy Services NHS UK

- Advising on missed or delayed doses of medicines - [link](#)
- Combined oral hormonal contraceptive (COC) in reproductive health - [updated PGD](#)
- Lidocaine injection for subdermal etonogestrel in contraception - [updated PGD](#)
- Ulipristal acetate 30mg tablets for emergency contraception - [updated PGD](#)
- Vitamin D deficiency: treatment during pregnancy - [link](#)
- Individually labelled medicines in residential custodial settings - [link](#)
- Preparing for audits and inspections of aseptic services - [link](#)

UK Health Security Agency

- Mosquito summary - HECC Chapter 8: climate and vector-borne diseases - [link](#)
- Whole genome sequencing service launched to tackle hepatitis C (HCV) - [link](#)

World Health Organisation (WHO)

- Japan's AMR response 2013-2025: developing, implementing and evaluating national AMR action plans - [link](#)
- Use of lower-sodium salt substitutes: WHO guideline - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Adanif (nifedipine) XL - depression added as ADR of unknown frequency
- Amvuttra (vutrisiran) pre-filled syringe - may be administered by a HCP, patient, or caregiver
- Butrans (buprenorphine) transdermal - concomitant use of buprenorphine with gabapentinoids may result in respiratory depression, hypotension, profound sedation, coma or death, and administration of buprenorphine with anticholinergics may result in increased anticholinergic adverse effects
- Camzyos hard capsules (mavacamten) - revised to advise that once an individualised maintenance dose is achieved with LVEF \geq 55%, patients should be assessed every 6 months (previously every 12 weeks). Assess patients with LVEF 50-55% every 3 months regardless of Valsalva LVOT gradient.
- Depo-Provera (medroxyprogesterone acetate) - meningioma or history of meningioma as a contra-indication to treatment; may be associated with prolonged treatment with (frequency unknown)
- Elvanse (lisdexamfetamine dimesylate), Elvanse Adult hard capsules - Tourette's disorder added as an ADR of unknown frequency in all age groups. Stimulants can exacerbate motor and phonic tics and Tourette's so clinical evaluation should precede use of these agents.
- Eylea (afibercept) - 'scleritis' added as an ADR and to note that there is 0.003mg of polysorbate 20 in each 0.01 ml dose (0.3 mg/ml)
- Episenta (sodium valproate) - carnitine supplementation should be considered when symptoms of hypocarnitaemia or hyperammonaemia are observed. Acquired Pelger-Huet anomaly added as a potential side effect of unknown frequency.
- Fosrenol (lanthanum carbonate hydrate) - bowel obstruction added as a contraindication
- Ixyldone (oxycodone) prolonged-release - Following PRAC recommendation, SPC updated to state "Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI)"
- Lioresal (baclofen) - cases of encephalopathy reported in patients receiving baclofen at therapeutic doses, which were reversible after treatment discontinuation. Symptoms included somnolence, depressed level of consciousness, confusion, myoclonus and coma.
- Movicol-Half - consider interactions in patients with swallowing problems, who need the addition of a thickener to solutions to enhance an appropriate intake, added back to section 4.4
- Moviprep, Plenvu - cases of seizures observed, mostly associated with electrolyte abnormalities. Cases of oesophageal rupture (Boerhaave syndrome) associated with excessive vomiting after intake have also been reported, mostly in elderly patients.
- Oxlumio (lumasiran sodium) - Undesirable effects and pharmacodynamic properties sections updated with information from the ILLUMINATE-A trial, including about long-term safety profile
- Paracetamol – all preparations - several sections updated to include information about high anion gap metabolic acidosis (HAGMA), following a recent PRAC recommendation for paracetamol-containing medicinal products
- Prograf (tacrolimus) – Kaposi's sarcoma (KS), including cases with aggressive forms of disease and fatal outcomes, reported in those taking tacrolimus. It notes, in some cases, regression of KS has been observed after reducing the intensity of immunosuppression.
- Salofalk (mesalazine) enema - idiopathic intracranial hypertension (pseudotumor cerebri) added as a potential ADR (frequency unknown). If it occurs, consider discontinuation of mesalazine.
- Solu-Cortef, Solu-Medrone (hydrocortisone sodium succinate) - cases of rhabdomyolysis reported with the use of corticosteroids (frequency unknown)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Spevigo (spesolimab) – several changes, including the addition of treatment of generalised pustular psoriasis flares in adolescents as monotherapy, and inclusion of dosing information for adolescents including those weighing ≥ 30 & < 40 kg. Information about hypersensitivity also updated
- Synjardy (empagliflozin/metformin) – additional information about prolonged ketoacidosis and glucosuria. Information about necrotising fasciitis also updated & additional information on elevated haematocrit added. Adverse effect information relating to phimosis/acquired phimosis also included
- Tecentriq (atezolizumab) - information regarding switching treatment between IV and subcutaneous formulations (and vice versa) added, based on results from an open-label cross-over study evaluating reported preferences in people with NSCLC
- Upravi (selexipag) - angioedema added as a common side-effect. Cases have been reported in post-marketing experience with a latency that can exceed 30 days of treatment.
- Zegluden (liraglutide) – cutaneous amyloidosis added ADR of unknown frequency. In this condition, amyloid or amyloid-like proteins are deposited in the dermis of the skin. May occur at the injection site

Food and Drug Administration (FDA) USA

- FDA issues class-wide labeling changes for testosterone products - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- Modified release opioids and treatment of post-operative Pain - [link](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Mpox vaccine and pericarditis - [update](#)
- Prescriber Update Vol. 46. No. 1 - [March 2025](#) – includes
- Spotlight on weekly methotrexate
- Medicines Monitoring: Anti-CD20 monoclonal antibodies and pyoderma gangrenosum
- Factors contributing to colchicine toxicity
- Medroxyprogesterone acetate and meningioma
- Sickle-cell crisis with pegfilgrastim and filgrastim
- Immune effector cell-associated neurotoxicity syndrome (ICANS)

MIMS monthly updates

- New Contraindications
- Carbamazepine ([Tegretol](#)) is now contraindicated in neonates below 4 weeks of age
- Clarithromycin ([Klacid](#)) is now contraindicated for concomitant use with ivabradine
- Esomeprazole (magnesium trihydrate), amoxicillin (trihydrate) and clarithromycin ([Nexium Hp7](#)) now contraindicated for concomitant use with ivabradine
- Triptorelin (embonate) ([Diphereline](#)) now contraindicated in patients where there are indications that the tumour is not hormone-dependent or following surgical castration

Pharma

- Astellas: Vezoza ▼ (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment - [letter](#)
- Medac: Sodiofolin® (folinic acid) 50mg/ml solution for injection/infusion – requirement to use a PES or PVDF filter for certain batches due to observation of particles and potential risk of thromboembolic event - [link](#)

Specialist Pharmacy Services NHS UK

- Medication Safety Update [February 2025](#)
- 'Flozin' suggestions for adults with swallowing difficulties - [link](#)
- 'Gliptin' suggestions for adults with swallowing difficulties - [link](#)
- Haemorrhoids: treatment during pregnancy - [link](#)

TGA

- Potential risk of neurodevelopmental disorders in children born to men taking sodium valproate - [link](#)
- More prominent warnings about serious side effects for fluoroquinolone antibiotics - [link](#)

- Valproate safety alert - [link](#)
- Strengthened warnings for broad-spectrum antibiotics - [link](#)

US Pharmacopeia

- 2024-2025 Vulnerable Medicines List for the United States: A data-based approach to identify risks and enable interventions to increase reliability of supply - [link](#)

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care - [link](#)
- Moral values for implementation of AI and machine learning in healthcare - [link](#)
- The impact of change in regulations on buprenorphine prescribing for opioid use disorder - [link](#)
- Impact of paralytic choice on postintubation sedation and analgesia in the emergency department - [link](#)
- The role of artificial intelligence in emergency medicine pharmacy practice - [link](#)

Annals of Internal Medicine

- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline - [link](#)
- In the clinic: Gout - [link](#)

Arthritis & Rheumatology

- Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis - [link](#)
- Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study - [link](#)
- Minimal Tofacitinib dose for Maintenance in Axial Spondyloarthritis: Real world data from a Resource-limited setting - [link](#)

British Journal of Clinical Pharmacology

- Adverse events associated with monoclonal antibodies used for treatment of COVID-19: A systematic review and meta-analysis - [link](#)
- Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective - [link](#)
- Assessing GPT-4's accuracy in answering clinical pharmacological questions on pain therapy - [link](#)
- Factors influencing physicians' antimicrobial prescribing decisions: A systematic review of qualitative studies - [link](#)
- Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross-sectional study - [link](#)
- Methotrexate toxicity and glucarpidase: A call for dose optimization - [link](#)

British Journal of Psychiatry

- Transdiagnostic use of 3,4-methylenedioxymethamphetamine-assisted therapy to treat obsessive-compulsive disorder - [link](#)

British Medical Journal (BMJ)

- Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study - [link](#)
- Shaping the UK's long term relationship with tirzepatide - [link](#)
- European Medicines Association upholds decision to recommend lecanemab for Alzheimer's disease - [link](#)
- Practice Pointer: Diagnosis and management of faecal incontinence in primary care - [link](#)
- Primary prevention of heart attacks and strokes: seeking consensus on the polypill approach - [link](#)

- Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021 - [link](#)
- Advances in the management of endometrial cancer - [link](#)

BMJ Open

- Efficacy and safety of 11 sodium-glucose cotransporter-2 inhibitors at different dosages in type 2 diabetes mellitus patients inadequately controlled with metformin: a Bayesian network meta-analysis - [link](#)
- Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes - [link](#)
- Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders - [link](#)
- Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden - [link](#)
- Can we trust published evidence on point-of-care tests for cholesterol? A rapid review - [link](#)
- Predictors of treatment REsponse to inhaled corticosteroids (ICS) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation-protocol of the ICS-RECODE individual participant data meta-analysis - [link](#)

Canadian Medical Association Journal (CMAJ)

- Effect of emergency department opioid prescribing on health outcomes - [link](#)

Circulation

- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes - [link](#)
- Efficacy of Irbesartan in Celiprolol-Treated Patients with Vascular Ehlers-Danlos Syndrome - [link](#)

Cochrane

- Rituximab for people with multiple sclerosis - [link](#)
- Safety and efficacy of proton pump inhibitors in preterm infants with gastroesophageal reflux disease - [link](#)
- Sulfonylurea drugs for people with severe hemispheric ischemic stroke - [link](#)
- Antidepressants for low back pain and spine-related leg pain - [link](#)
- Vasodilators for women undergoing fertility treatment - [link](#)
- Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis - [link](#)
- Renin inhibitors versus angiotensin receptor blockers for primary hypertension - [link](#)

Critical Care Medicine

- A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU - [link](#)
- Acetylsalicylic Acid Treatment in Patients With Sepsis and Septic Shock: A Phase 2, Placebo-Controlled, Randomized Clinical Trial - [link](#)

Diabetes Care

- Early Continuous Glucose Monitor Use in Children and Adolescents With Type 1 Diabetes: Rates of Initiation and Impact on Glycemic Outcomes - [link](#)
- Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease - [link](#)
- Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes - [link](#)

Diabetes, Obesity and Metabolism

- Temporal risk patterns of severe hypovolemia associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A self-controlled case series study - [link](#)

Drug and Therapeutics Bulletin

- DTB Editorial: Paying the price - [link](#)

European Heart Journal

- Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study - [link](#)
- Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial - [link](#)
- Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months - [link](#)

European Journal of Hospital Pharmacy

- Unit dose drug dispensing systems in hospitals: a systematic review of medication error reduction and cost-effectiveness - [link](#)
- Adherence and persistence rates for antidiabetic treatments in type 2 diabetes: a real-world study in an Italian region - [link](#)

Heart

- Cardiovascular health effects of vaping e-cigarettes: a systematic review and meta-analysis - [link](#)
- Missed opportunities to manage complex comorbidity of heart failure, type 2 diabetes mellitus and chronic kidney disease: a retrospective cohort study - [link](#)
- Evolution of coronary stents: innovations, antithrombotic strategies and future directions - [link](#)
- Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era - [link](#)

Internal Medicine Journal

- Results of rapid plasma direct oral anticoagulant levels greatly expand stroke thrombolysis eligibility: evidence from real-world implementation - [link](#)
- Performance and opportunity: retrospective cohort study of general medicine heart failure management - [link](#)

International Journal of Clinical Pharmacy

- Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis - [link](#)
- Investigating the controversy surrounding statin therapy and Achilles tendinopathy using Mendelian randomization analysis - [link](#)

International Journal for Quality in Health Care

- Look-Alike, Sound-Alike Medication Perioperative Incidents in a Regional Australian Hospital: Assessment using a Novel Medication Safety Culture Assessment Tool - [link](#)

JAC - Antimicrobial resistance

- Assessing the impact of using a patient counselling prompt—the TARGET antibiotic checklist in England's community pharmacies - [link](#)

JAMA

- Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial - [link](#)
- Testicular Germ Cell Tumors: A Review - [link](#)
- Eating Disorders: A Review - [link](#)
- HIV Viral Suppression with Use of Long-Acting Antiretroviral Therapy in People With and Without Initial Viremia - [link](#)
- High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Prostate Cancer: A Review - [link](#)

JAMA Cardiology

- Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF - [link](#)
- Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure with Preserved Ejection Fraction - [link](#)

JAMA Dermatology

- Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure - [link](#)
- At-Home LED Devices for the Treatment of Acne Vulgaris: A Systematic Review and Meta-Analysis - [link](#)
- Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis - [link](#)
- Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials - [link](#)
- Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris - [link](#)
- Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial - [link](#)

JAMA Internal Medicine

- Multivitamins After Myocardial Infarction in Patients with Diabetes: A Randomized Clinical Trial - [link](#)
- Expanding Alcohol Use Disorder Medications in Primary Care - [link](#)
- Butter and Plant-Based Oils Intake and Mortality - [link](#)

JAMA Network Open

- Hematologic Cancers Among Patients with Type 2 Diabetes Prescribed GLP-1 Receptor Agonists - [link](#)

JAMA Neurology

- Frailty and Implications for Multiple Sclerosis Management - [link](#)
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials - [link](#)

JAMA Oncology

- Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens - [link](#)
- Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial - [link](#)

JAMA Ophthalmology

- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy - [link](#)

JAMA Psychiatry

- Evidence-Based Practicing in Mental Health - [link](#)

Joint Commission Journal on Quality and Patient Safety

- Editorial: The Invisible Work to Manage Drug Shortages – [link](#)
- Reflections on a Dobutamine Shortage in an Academic Health System: A Roadmap for Risk Reduction - [link](#)

Journal of Clinical Oncology

- Therapy for Stage IV Non–Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2024.3 - [link](#)
- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 - [link](#)

- Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor-Positive Early Breast Cancer: A Nationwide Cohort Study – [link](#)

Journal of Patient Safety

- Ambulatory medication errors and adverse events involved in medicine-related malpractice cases from 2011 to 2021 - [link](#)

Journal of Pharmaceutical Policy and Practice

- Medication-focused telehealth interventions to reduce the hospital readmission rate: a systematic review - [link](#)

Lancet

- Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial - [link](#)

- Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial - [link](#)

- Zika Virus: Research Priorities for Preparedness and Response - [link](#)

- Efficacy and safety of twice per year dupilumab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials - [link](#)

- Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial - [link](#)

- Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 - [link](#)

- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 - [link](#)

- Tuberculosis - [link](#)

- Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials - [link](#)

Lancet Diabetes & Endocrinology

- Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials - [link](#)

- GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study - [link](#)

- A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia - [link](#)

- Adrenocortical carcinoma: a practical guide for clinicians - [link](#)

Lancet Gastroenterology and Hepatology-

- The urgent need for implementation science to achieve hepatitis C elimination - [link](#)

- Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study - [link](#)

- The intestinal barrier: a pivotal role in health, inflammation, and cancer - [link](#)

Lancet Infectious Diseases

- Antimicrobials in serious illness and end-of-life care: lifting the veil of silence - [link](#)

- Facts and myths about measles - [link](#)

Lancet Oncology

- Dose optimisation to improve access to effective cancer medicines - [link](#)

- Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Lancet Psychiatry

- Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses - [link](#)
- Hospital Clinicians' Knowledge of and Opportunity and Motivation for Prescribing Short Antibiotic Courses for Common Infections - [link](#)

Medical Journal of Australia

- National consensus statement on opioid agonist treatment in custodial settings - [link](#)
- Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus [statement](#)
- Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability - [link](#)
- Making climate change a national health priority: Australia's first National Health and Climate Strategy - [link](#)
- Improving palliative care for people who use alcohol and other drugs - [link](#)
- A future for the hospital-in-the-home (HITH) deteriorating patient: shifting the paradigm - [link](#)
- Potentially preventable medication-related hospitalisations with cardiovascular disease of Aboriginal and Torres Strait Islander people, Queensland, 2013–2017: a retrospective cohort study - [link](#)

Nature Medicine

- Global patterns and trends in breast cancer incidence and mortality across 185 countries - [link](#)

New England Journal of Medicine

- Oral Infigratinib Therapy in Children with Achondroplasia - [link](#)
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps - [link](#)
- Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis - [link](#)
- Remibrutinib in Chronic Spontaneous Urticaria - [link](#)
- Micronutrients — Assessment, Requirements, Deficiencies, and Interventions - [link](#)
- Supporting the Development of Drugs for Rare Diseases —The Importance of Regulatory Transparency - [link](#)

Pediatrics (American Academy of Pediatrics)

- GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity - [link](#)
- Recommendations for Pneumonia in Hospitalized Children With Neurologic Impairment - [link](#)
- Adapting a Risk Prediction Tool for Neonatal Opioid Withdrawal Syndrome - [link](#)

Pharmaceutical Journal

- Understanding the role of sex hormones in asthma - [link](#)

Pharmacotherapy

- Evaluation of hyponatremia among older adults exposed to selective serotonin reuptake inhibitors and thiazide diuretics - [link](#)
- Prevalence of potentially inappropriately prescribed medications among older adults receiving peritoneal dialysis - [link](#)

Prescrire International – [March 2025](#) issue includes:

- Exagamglogene autotemcel (Casgevy[®]) in beta-thalassaemia or sickle-cell disease
- Children exposed to progestogens in utero: excess cancers?
- Anticoagulants and heavy menstrual bleeding

Thorax

- Impact of COPD on cardiovascular risk factors and outcomes in people with established cardiovascular disease - [link](#)

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Neonatal jaundice and hyperbilirubinaemia, closes 4 April 2025 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 183](#): Drug safety in pregnancy

Canadian Pharmacists Association

- Beyond the numbers: A pharmacist's guide to dyslipidemia management and clinical decision-making - [link](#)

FDA Division of Drug Information is presenting a [series](#) of CE webinars

- An Update on Transmucosal Buprenorphine and Dental Caries - [December 10, 2024](#)

MJA Podcasts

- [Episode 5](#): Gender inequality in health

UPCOMING EVENTS

AHHA

- Investing in DIAMONDS: transforming a surgical waitlist into a 'preparation list', online 1 April, 2025 12:30-13:30 AEDT - [register](#)
- Mental Health Access & Quality in Emergency Departments, April 8, 2025 09:00 AEST – [register](#)

Australian Centre for Value-Based Health Care

- 2025 Congress: Partnering to advance VBHC in Australia, 1-2 May 2025, Melbourne - [register](#)